According to Wuxi Biologics's official Wechat news, the company today announced a strategic cooperation with AstraZeneca PLC on the localization of COVID-19 's anti-neutralizing antibody combination drug Enshi (Evusheld, formerly known as AZD7442). AstraZeneca PLC and COVID-19 anti-neutralization antibody combination drugs were authorized for emergency use in the United States at the end of last year, listed in the European Union in March this year and conditionally listed in the United Kingdom, and were conditionally approved by the Hong Kong Department of Health in May this year. In June this year, it passed the special import approval of the Boao Lecheng International Medical Tourism advance Zone in Hainan for novel coronavirus pre-exposure prevention. At present, the drug has been approved and supplied in many countries around the world.